A Four-Week Multicenter Study Evaluating the Safety and Efficacy of AF-219 in Subjects With Osteoarthritis of the Knee.
Phase of Trial: Phase II
Latest Information Update: 24 May 2017
At a glance
- Drugs Gefapixant (Primary)
- Indications Musculoskeletal pain
- Focus Therapeutic Use
- Sponsors Afferent Pharmaceuticals
- 22 Jan 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 09 Sep 2013 Results are expected in mid-2014 according to an Afferent Pharmaceuticals media release.
- 31 Jul 2013 Planned End Date changed from 1 Oct 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.